Feenstra M, Bakema J, Verdaasdonk M, Rozemuller E, van den Tweel J, Slootweg P, de Weger R, Tilanus M
Department of Pathology, University Hospital, Utrecht, The Netherlands.
Genes Chromosomes Cancer. 2000 Jan;27(1):26-34. doi: 10.1002/(sici)1098-2264(200001)27:1<26::aid-gcc4>3.0.co;2-x.
HLA class I and beta-2-microglobulin (beta2m) expression in a moderately differentiated laryngeal squamous cell carcinoma appeared to be downregulated when analyzed by immunohistochemical procedures using the monomorphic anti-HLA class I monoclonal antibody (mAb; W6/32), locus-specific (HCA2 and HC10) and allele-specific (LT129.11 and KRE501) mAbs and anti-beta2m mAbs. To reveal the molecular basis of downregulated HLA class I expression, HLA-A typing was performed on DNA derived from peripheral blood lymphocytes (PBL) and the tumor. Sequencing-based typing (SBT) revealed HLA-A02011, 31012. In addition to HLA-A02011, 31012 alleles, the tumor contained an HLA-A31012 allele, which lacked all introns when sequenced from the initiation codon through exon eight. The 3' UTR region was intact up to at least 200 bp downstream. The mutant HLA-A31012 is restricted to laryngeal tumor tissue since it was not amplified in flanking tumor-free laryngeal tissue. The mutant HLA-A31012 shares structural characteristics with processed pseudogenes, i.e., absence of introns and an intact 3' UTR. This indicates that the mutant HLA-A31012 allele resulted from a retroposition (reverse transcription and integration) from the processed transcript of the wild-type HLA-A*31012 allele within a clonal tumor cell. Genes Chromosomes Cancer 27:26-34, 2000.
当使用单克隆抗HLA I类单克隆抗体(mAb;W6/32)、位点特异性(HCA2和HC10)和等位基因特异性(LT129.11和KRE501)mAb以及抗β2m mAb通过免疫组织化学方法进行分析时,中度分化的喉鳞状细胞癌中HLA I类和β2-微球蛋白(β2m)的表达似乎下调。为了揭示HLA I类表达下调的分子基础,对来自外周血淋巴细胞(PBL)和肿瘤的DNA进行了HLA-A分型。基于测序的分型(SBT)显示为HLA-A02011、31012。除了HLA-A02011、31012等位基因外,肿瘤还包含一个HLA-A31012等位基因,从起始密码子到外显子八进行测序时,该等位基因缺乏所有内含子。3'UTR区域在下游至少200 bp处是完整的。突变型HLA-A31012仅限于喉肿瘤组织,因为在侧翼无肿瘤的喉组织中未扩增到。突变型HLA-A31012与加工后的假基因具有结构特征,即缺乏内含子和完整的3'UTR。这表明突变型HLA-A31012等位基因是由野生型HLA-A*31012等位基因加工后的转录本在克隆肿瘤细胞内逆转录(反转录和整合)产生的。《基因、染色体与癌症》27:26 - 34,2000年。